Trial Profile

A Phase 1, First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 Following Randomized, Double-blind, Placebo-controlled Single Ascending Doses in Healthy Subjects and Patients (PBC/PSC)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PVT 201 (Primary)
Indications Autoimmune hepatitis; Liver transplant rejection; Non-alcoholic steatohepatitis; Primary biliary cirrhosis; Primary sclerosing cholangitis
Focus Adverse reactions; First in man
Sponsors Parvus Therapeutics

28 May 2025 Planned End Date changed from 1 Feb 2025 to 1 Jun 2025.
28 May 2025 Planned primary completion date changed from 1 Feb 2025 to 1 Jun 2025.
04 Feb 2025 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com